IL6 and congenital rubella syndrome: Finally, analysis of 37 cytokines, including IL-6, assessed with CAR NK monotherapy or combination therapy of OV-1L15C and EGFR-CAR NK-cells did not demonstrate significant differences in cytokine expression, suggesting a low risk of CRS.